Evidence map›Paper›PMID 40343955›Full record

ArticlePLOS global public health2025

Pre-exposure prophylaxis (PrEP) awareness, use, and discontinuation among Lake Victoria fisherfolk in Uganda: A cross-sectional population-based study.

Kauthrah Ntabadde, Joseph Kagaayi, Victor Ssempijja, Xinyi Feng, Robert Kairania, Joseph Lubwama, Robert Ssekubugu, Ping Teresa Yeh, Joseph Ssekasanvu, Aaron A R Tobian and 10 more

Erratum issuedAbstract read
In one paragraph

Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Kauthrah NtabaddeBloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0002-6130-6535
Joseph KagaayiRakai Health Sciences Program, Kalisizo, Uganda.
Victor SsempijjaRakai Health Sciences Program, Kalisizo, Uganda.
Xinyi FengDepartment of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
Robert KairaniaRakai Health Sciences Program, Kalisizo, Uganda.
Joseph LubwamaRakai Health Sciences Program, Kalisizo, Uganda.
Robert SsekubuguRakai Health Sciences Program, Kalisizo, Uganda.
Ping Teresa YehDepartment of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.
Joseph SsekasanvuBloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.
Aaron A R TobianDepartment of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
Caitlin E KennedyDepartment of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.
Lisa A MillsDivision of Global HIV & TB, United States Centers for Disease Control and Prevention - Uganda, Kampala, Uganda.
Stella AlamoDivision of Global HIV & TB, United States Centers for Disease Control and Prevention - Uganda, Kampala, Uganda.
Philip KreniskeDepartment of Community Health and Social Sciences, Graduate School of Public Health and Health Policy, City University of New York, New York, New York, United States of America.
John SantelliDepartment of Population and Family Health and Pediatrics, Mailman School of Public Health, Columbia University, New York, New York, United States of America.
Lisa J NelsonDivision of Global HIV & TB, United States Centers for Disease Control and Prevention - Uganda, Kampala, Uganda.
Steven J ReynoldsRakai Health Sciences Program, Kalisizo, Uganda.ORCID https://orcid.org/0000-0002-5403-2759
Larry William ChangRakai Health Sciences Program, Kalisizo, Uganda.
Gertrude NakigoziRakai Health Sciences Program, Kalisizo, Uganda.
Mary Kate GrabowskiBloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0002-4451-3436

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
Structural and Social Transitions Among Adolescents in Rakai (SSTAR)R01HD091003 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SANTELLI, JOHN S. · 2017 to 2021
$3.7M
RCT to reduce HIV acquisition and viral load among migrants, Rakai, UgandaR01MH115799 · NIMH · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM, WAWER, MARIA J · 2018 to 2022
$2.9M
Hard-to-Reach Populations: Implications for Ending the AIDS EpidemicR01AI143333 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2019 to 2022
$2.4M
Multidisciplinary Research Training to Understand and Reduce HIV Incidence in UgandaD43TW010557 · FIC · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2018 to 2022
$1.6M
FIC NIH HHS D43 TW010557NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI143333NICHD NIH HHS R01 HD091003NIMH NIH HHS R01 MH115799
6 · The paper itself

Abstract

There is limited population-level data on the pre-exposure prophylaxis (PrEP) care continuum in eastern Africa. Here, we assessed the PrEP care continuum following PrEP rollout in a Ugandan community with ~40% HIV seroprevalence. We used cross-sectional population-based data collected between September 3 and December 19, 2018 from a Lake Victoria fishing community in southern Uganda to measure levels of self-reported PrEP awareness, ever-use, and discontinuation following 2017 PrEP rollout via a U.S. President's Emergency Plan for AIDS Relief (PEPFAR)-supported phased implementation program. Our analysis included HIV-seronegative persons reporting having ever received an HIV test result. We examined associations between demographic, behavioral, and health utilization factors with each outcome using age-adjusted modified Poisson regression. There were 1,401 HIV-seronegative participants, of whom 1,363 (97.3%) reported ever receiving an HIV test result. Median age was 29 years (IQR: 23-36), and 42.3% (n = 577) were women. Most (85.5%; n = 1,166/1363) participants reported PrEP awareness, but few (14.5%; n = 197/1363) reported ever using PrEP. Among 47.7% (375/786) of men and 29.3% (169/577) of women PrEP-eligible at time of survey, 18.9% (n = 71/375) and 27.8% (n = 47/169) reported ever using PrEP, respectively. Over half (52.3%, n = 103/197) of those who had ever used PrEP, self-reported current use. In this Lake Victoria fishing community, there were low levels of PrEP use despite high levels of PrEP awareness and eligibility, particularly among men. Efforts that enhance awareness of HIV risk and increase PrEP accessibility may help increase PrEP use among HIV-seronegative persons in African settings with high HIV burden.

Identifiers

PMID40343955
PMCPMC12063894

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.